Randomized trial · people
SS-31: wearable data grouped responders with 100% accuracy
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For elamipretide in Barth syndrome, this early work suggests wearable readings could one day help spot who responds, but it does not measure the drug's benefit itself.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 12
- Published
- 2023
- Journal
- Orphanet J Rare Dis
What they tested
Could data from a wearable device tell apart people with Barth syndrome who did better or worse on elamipretide (SS-31), and predict how well they function?
How the study was done
A further analysis of a randomized, double-blind, placebo-controlled crossover trial (each person got both elamipretide and placebo, a dummy treatment, at different times) in 12 patients with Barth syndrome, a rare inherited disease that affects the heart and muscles. The team fed wearable readings of heart rate, breathing rate, activity and posture into a clustering model, a computer method that sorts people into groups by how alike their data look.

What they found
Patients were split at the middle value of each functional test into higher and lower scorers, and into best and worst responders to elamipretide. Sorting by functional level matched the real groups 60-93% of the time, with the best results for the 6-minute walk test (93%), the PROMIS fatigue score (87%) and the SWAY balance score (80%). Sorting by response to elamipretide matched the real groups in every case (100%).
What it doesn’t show
This was a small proof-of-concept study in 12 patients. It tested whether wearable data can sort patients into groups, not how much elamipretide helped, and responders were defined only as the better half of the group on each test.
The paper
Van den Eynde et al. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. Orphanet J Rare Dis. 2023.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.